Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab

Gomez-Martin, Carlos, Plaza, Jose Carlos, Pazo-Cid, Roberto, Salud, Antonieta, Pons, Francesc, Fonseca, Paula, Leon, Ana, Alsina, Maria, Visa, Laura, Rivera, Fernando, Galan, M. Carmen, del Valle, Elena, Vilardell, Felipe, Iglesias, Mar, Fernandez, Soledad, Landolfi, Stefania, Cuatrecasas, Miriam, Mayorga, Marta, Jose Paulés, M., Sanz-Moncasi, Pilar, Montagut, Clara, Garralda, Elena, Rojo, Federico, Hidalgo, Manuel, Lopez-Rios, Fernando · 2013 · Journal of Clinical Oncology

Abstract

Purpose: Previous studies have highlighted the importance of an appropriate human epidermal growth factor receptor 2 (HER2) evaluation for the proper identification of patients eligible for treatment with anti-HER2 targeted therapies. Today, the relationship remains unclear between the level of HER2 amplification and the outcome of HER2-positive gastric cancer treated with first-line chemotherapy with trastuzumab. The aim of this study was to determine whether the level of HER2 gene amplification determined by the HER2/CEP17 ratio and HER2 gene copy number could significantly predict some benefit in overall survival and response to therapy in advanced gastric cancer treated with trastuzumab-based chemotherapy. Patients and Methods: Ninety patients with metastatic gastric cancer treated with first-line trastuzumab-based chemotherapy were studied. The optimal cutoff values for HER2/CEP17 ratio and HER2 gene copy number (GCN) for discriminating positive results in terms of response and prolonged survival were determined using receiver operating characteristic curves analyses. Results: In this study, a median HER2/CEP17 ratio of 6.11 (95% CI, 2.27 to 21.90) and a median HER2 gene copy number of 11.90 (95% CI, 3.30 to 43.80) were found. A mean HER2/CEP17 ratio of 4.7 was identified as the optimal cutoff value discriminating sensitive and refractory patients (P = .005). Similarly, the optimal cutoff for predicting survival longer than 12 months was 4.45 (P = .005), and for survival longer than 16 months was 5.15 (P = .004). For HER2 GCN, the optimal cutoff values were 9.4, 10.0, and 9.5, respectively (P = .02). Conclusion: The level of HER2 gene amplification significantly predicts sensitivity to therapy and overall survival in advanced gastric cancer treated with trastuzumab-based chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.48.9070

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 189

Metadata

Authors
Gomez-Martin, C., Plaza, J. C., Pazo-Cid, R., Salud, A., Pons, F., Fonseca, P., Leon, A., Alsina, M., Visa, L., Rivera, F., Galan, M. C., del Valle, E., Vilardell, F., Iglesias, M., Fernandez, S., Landolfi, S., Cuatrecasas, M., Mayorga, M., Jose Paulés, M., Sanz-Moncasi, P., Montagut, C., Garralda, E., Rojo, F., Hidalgo, M., & Lopez-Rios, F.
Venue
Journal of Clinical Oncology
Published
2013-12-10
Volume
31
Issue
35
Pages
4445-4452
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2171136968
Cited by
189
References
4
FWCI
15.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. https://app.cochat.ai/papers/10.1200/jco.2013.48.9070
The paper
Gomez-Martin, C., Plaza, J. C., Pazo-Cid, R., Salud, A., Pons, F., Fonseca, P., Leon, A., Alsina, M., Visa, L., Rivera, F., Galan, M. C., del Valle, E., Vilardell, F., Iglesias, M., Fernandez, S., Landolfi, S., Cuatrecasas, M., Mayorga, M., Jose Paulés, M., . . . Lopez-Rios, F. (2013). Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.48.9070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.